| Title |
Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial
|
|---|---|
| Published in |
PLOS ONE, February 2010
|
| DOI | 10.1371/journal.pone.0009041 |
| Pubmed ID | |
| Authors |
Mahamadou A. Thera, Ogobara K. Doumbo, Drissa Coulibaly, Matthew B. Laurens, Abdoulaye K. Kone, Ando B. Guindo, Karim Traore, Mady Sissoko, Dapa A. Diallo, Issa Diarra, Bourema Kouriba, Modibo Daou, Amagana Dolo, Mounirou Baby, Mahamadou S. Sissoko, Issaka Sagara, Amadou Niangaly, Idrissa Traore, Ally Olotu, Olivier Godeaux, Amanda Leach, Marie-Claude Dubois, W. Ripley Ballou, Joe Cohen, Darby Thompson, Tina Dube, Lorraine Soisson, Carter L. Diggs, Shannon L. Takala, Kirsten E. Lyke, Brent House, David E. Lanar, Sheetij Dutta, D. Gray Heppner, Christopher V. Plowe |
| Abstract |
The objective was to evaluate the safety and immunogenicity of the AMA1-based malaria vaccine FMP2.1/AS02(A) in children exposed to seasonal falciparum malaria. |
Mendeley readers
The data shown below were compiled from readership statistics for 157 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 2 | 1% |
| United States | 2 | 1% |
| United Kingdom | 2 | 1% |
| Burkina Faso | 1 | <1% |
| Norway | 1 | <1% |
| Spain | 1 | <1% |
| Peru | 1 | <1% |
| Unknown | 147 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 26 | 17% |
| Student > Ph. D. Student | 25 | 16% |
| Student > Master | 19 | 12% |
| Student > Bachelor | 13 | 8% |
| Student > Postgraduate | 8 | 5% |
| Other | 27 | 17% |
| Unknown | 39 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 46 | 29% |
| Medicine and Dentistry | 30 | 19% |
| Immunology and Microbiology | 10 | 6% |
| Biochemistry, Genetics and Molecular Biology | 7 | 4% |
| Nursing and Health Professions | 5 | 3% |
| Other | 20 | 13% |
| Unknown | 39 | 25% |